3rd Floor, Zhongguancun Dongsheng Intl. S No. 1 North Yongtaizhuang Road Haidian Dist.
|Dr. Zhi Hong Ph.D.||Co-founder, Exec. Chairman & CEO||無||無||1964|
|Dr. Ankang Li C.F.A., J.D., Ph.D.||Chief Financial & Strategy Officer and Company Sec.||無||無||無|
|Ms. Karen Del Barrio Neuendorff||Chief People Officer & Head of HR||無||無||無|
|Mr. Yongqing Luo||Pres & GM of Greater China, CEO of TSB Therapeutics and Exec. Director||無||無||無|
|Mr. Coy Stout||Sr. VP, Head of U.S. Market Access & Patient Advocacy||無||無||無|
|Dr. Li Yan M.D., Ph.D.||Chief Medical Officer||無||無||無|
|Dr. Lianhong Xu Ph.D.||Sr. VP & Head of Medicinal Chemistry||無||無||無|
|Dr. Qing Zhu Ph.D.||Sr. VP & Head of Biopharmaceutical Research||無||無||無|
|Dr. David Margolis M.D., M.P.H.||VP & Head of Infectious Diseases Therapy Area||無||無||無|
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
截至 無 止，騰盛博藥－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。